Rifacol 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Sharif pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Semisynthetic, rifamycin-based non-systemic antibiotic. Inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. Broad spectrum activity against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- Traveler's Diarrhea: 200 mg 3 times daily for 3 days (patients ≥12 years of age)
- Hepatic Encephalopathy: 550 mg 2 times daily (patients ≥18 years of age)
- Bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Can be taken with or without food
Interaction
In vitro study suggests induction of CYP3A4, but not expected to induce CYP3A4 in patients with normal liver function at recommended dosing.
Contraindications
Hypersensitivity to Rifaximin or any of the rifamycin antimicrobial agents, or any components of this product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Reactions including anaphylaxis, angioneurotic edema, and exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. Excretion in human milk unknown.
Precautions & Warnings
Not effective in patients with diarrhea complicated by fever and/or blood in the stools. Discontinue therapy if symptoms worsen or persist for more than 24-48 hours. Consider alternative antibiotic therapy. Pseudomembranous colitis may occur.
Use in Special Populations
- Renal Impairment: Pharmacokinetics in patients with impaired renal function not studied
- Hepatic Impairment: Markedly elevated systemic exposure in patients with hepatic impairment compared to healthy subjects
Overdose Effects
No specific information on treatment. Discontinue, treat symptomatically, and institute supportive measures as required.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C, away from light and moisture. Keep out of the reach of children.